Form 4: Pharvaris Executive Executes Scheduled Stock Sales

Chief Early Development Officer Anne Lesage exercised options and sold shares of Pharvaris N.V. under a pre-arranged 10b5-1 trading plan.

Summary

• Anne Lesage, Chief Early Development Officer at Pharvaris N.V., exercised stock options to acquire 25,400 shares of common stock.
• The exercises occurred on April 29 and April 30, 2026, at strike prices of $2.59 and $8.05 per share.
• Following the exercises, the executive sold a total of 44,600 shares (including direct holdings and shares held by GrayMatters Consulting B.V.) at prices ranging between $30.00 and $30.75 per share.
• All transactions were executed pursuant to a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine portfolio management by an executive.

Positives

• Transactions were conducted under a pre-established 10b5-1 plan, indicating the sales were scheduled rather than reactive to non-public information.
• The executive maintains a significant remaining stake in the company, with 56,450 shares held directly and 133,969 shares held indirectly.

Negatives

• The filing reflects a reduction in the executive's total beneficial ownership of Pharvaris common stock.

Risks

• Future share price volatility could impact the value of remaining holdings.
• Reliance on 10b5-1 plans does not eliminate the risk of market perception regarding insider selling.

Future Outlook

No forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and is generally viewed as neutral by the market unless the volume of shares sold represents a significant portion of the executive's total holdings.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for biotech executives to avoid potential conflicts of interest regarding insider trading regulations.

Related Party Transactions

• Sales were conducted by GrayMatters Consulting B.V., an entity controlled by Dr. Anne Lesage.

Stakeholder Impact

• Minimal impact expected as the sales were executed under a pre-planned 10b5-1 arrangement.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Pharvaris, PHVS, Insider Trading, Form 4, Stock Options, 10b5-1